Ganaplacide/ Lumefantrine

Novartis

Legend
Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Potential for prophylaxis
MoA

  • Not yet determined. Decreased susceptibility to ganaplacide is associated with mutations in three P. falciparum genes, CARL (cyclic amine resistance locus), UDP-galactose and Acetyl-CoA transporters
Key features

Ganaplacide

  • Novel mechanism of action – activity against parasites that are resistant to current drugs

  • Rapid killing of parasites (parasite clearance time <48 hours)

  • 800mg human dose stays above Minimal Parasiticidal Concentration for >8 days

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

  • Potential for prophylaxis due to effect on parasite liver stage 

Lumefantrine

  • New lumefantrine formulation with improved bioavailability
Status

  • Phase llb combination study ongoing
Next milestone

  • Phase llb study completion 

  • Start of phase IIb study in paediatric population (0.5 to <12 years)
Previously

  • Previous names: KAF156, GNF156. Discovery partnership between MMV, Wellcome Trust, Novartis, and the Swiss Tropical and Public Health Institute
MMV Project Director
  • Dr Gonzalo Acuña